+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Schizophrenia Drugs (Orals & Injectables) Market: Insights, Trends and Forecast (2019-2023)

  • ID: 4849539
  • Report
  • October 2019
  • Region: Global
  • 95 Pages
  • Koncept Analytics
10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Alkermes Plc
  • Allergan Plc
  • Johnson & Johnson
  • Otsuka Holdings Co., Ltd.
  • MORE

The global schizophrenia market is estimated to reach US$10.43 billion in 2023, growing at a CAGR of 3.69%, for the period spanning from 2018 to 2023. The factors such as the rising occurrence of schizophrenia, surging chronic ailments incidence, increasing personal healthcare expenditure, accelerating economic growth and unmet medical needs are expected to drive the market growth. However, growth of the industry would be challenged by stringent regulations, patient health-associated risk, associated business risk and limited access to patent rights. A few notable trends include rising pharmaceutical R&D spending, intensifying e-commerce pharmaceutical products sales, progressing schizophrenia drugs pipeline and rising adoption of somatic therapy.

On the basis of mode of administration, the schizophrenia market has been segmented into long acting injections and oral. Amongst them, owing to effective long-term relapse prevention, increased patient compliance, ease of administration and reduced hospitalization rates, long acting injections are widely used for managing or treating schizophrenia patients.

The fastest growing regional market is America owing to continuous advancement in the second & third generation antipsychotic drugs, increasing schizophrenia population and development of economical long acting drugs by local manufacturers in the US and Canada. The US is the largest market and is already well-penetrated at developed market levels.

Scope of the report:

  • The report provides a comprehensive analysis of the global schizophrenia market, segmented on the basis of mode of administration i.e. oral & long acting injections, by therapeutic class i.e. second & third generation anti-psychotics and drug type i.e. Invega Sustenna, Latuda, Arsitada & Rexulti.
  • The major regional markets (Americas, Europe and Asia-Pacific) have been analysed, along with country coverage of the U.S, Germany and Japan.
  • The market dynamics such as growth drivers, market trends and challenges are analysed in-depth.
  • The competitive landscape of the market, along with the company profiles of leading players (Allergan Plc, Johnson & Johnson, Otsuka Holdings Co., Ltd., Sumitomo Chemical Co., Ltd., Alkermes Plc and Acadia Pharmaceuticals Inc.) are also presented in detail.

Key Target Audience:

  • Drug Manufacturers
  • Raw Material Suppliers
  • End Users
  • Consulting Firms
  • Investment Banks
  • Government Bodies & Regulating Authorities


Please note: 10% free customization equates to up to 3 hours of analyst time.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Alkermes Plc
  • Allergan Plc
  • Johnson & Johnson
  • Otsuka Holdings Co., Ltd.
  • MORE

1. Market Overview
1.1 Introduction
1.2 Causes
1.3 Symptoms
1.4 Diagnosis
1.5 Treatment

2. Global Schizophrenia Market Analysis
2.1 Global Schizophrenia Market Value Forecast
2.2 Global Schizophrenia Market Value by Mode of Administration
2.2.1 Global Long Acting Injections Schizophrenia Market Value Forecast
2.2.2 Global Oral Schizophrenia Market Value Forecast
2.3 Global Schizophrenia Market Value by Therapeutic Class
2.3.1 Global Second Generation Anti-Psychotic Market Value Forecast
2.3.2 Global Third Generation Anti-Psychotic Market Value Forecast
2.4 Global Schizophrenia Market Value by Drug Type
2.4.1 Global Invega Sustenna Drug Value Forecast
2.4.2 Global Latuda Drug Value Forecast
2.4.3 Global Aristada Drug Value Forecast
2.4.4 Global Rexulti Drug Value Forecast
2.5 Global Schizophrenia Market Value by Region

3. Regional Schizophrenia Market Analysis
3.1 Americas
3.1.1 Americas Schizophrenia Market Value Forecast
3.1.2 The U.S. Schizophrenia Market Value Forecast
3.1.3 The U.S. Schizophrenia Market Value by Mode of Administration
3.1.4 The U.S. Long Acting Injections Schizophrenia Market Value Forecast
3.1.5 The U.S. Oral Schizophrenia Market Value Forecast
3.2 Europe
3.2.1 Europe Schizophrenia Market Value Forecast
3.2.2 Europe Schizophrenia Market Value by Mode of Administration
3.2.3 Europe Oral Schizophrenia Market Value Forecast
3.2.4 Europe Long Acting Injections Schizophrenia Market Value Forecast
3.2.5 Germany Schizophrenia Market Value Forecast
3.3 Asia-Pacific
3.3.1 Asia-Pacific Schizophrenia Market Value Forecast
3.3.2 Japan Schizophrenia Market Value Forecast

4. Market Dynamics
4.1 Growth Drivers
4.1.1 Rising Occurrence of Schizophrenia
4.1.2 Surging Chronic Ailments Incidence
4.1.3 Increasing Personal Healthcare Expenditure
4.1.4 Accelerating Economic Growth
4.1.5 Unmet Medical Needs
4.2 Key Trends and Developments
4.2.1 Rising Pharmaceutical R&D Spending
4.2.2 Intensifying E-Commerce Pharmaceutical Products Sales
4.2.3 Progressing Schizophrenia Drugs Pipeline
4.2.4 Rising Adoption of Somatic Therapy
4.3 Challenges
4.3.1 Stringent Regulations
4.3.2 Patient Health-Associated Risk
4.3.3 Associated Business Risk
4.3.4 Limited Access to Patent Rights

5. Competitive Landscape
5.1 Global Schizophrenia Market
5.1.1 Key Players – Revenue Comparison
5.1.2 Key Players – Market Cap Comparison
5.1.3 Key Players – Research & Development Expenditure Comparison
5.1.4 Key Players – Drug Features Comparison

6. Company Profiles
6.1 Allergan Plc
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Johnson & Johnson
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Otsuka Holdings Co., Ltd.
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Sumitomo Chemical Co., Ltd.
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
6.5 Alkermes Plc
6.5.1 Business Overview
6.5.2 Financial Overview
6.5.3 Business Strategies
6.6 Acadia Pharmaceuticals Inc.
6.6.1 Business Overview
6.6.2 Financial Overview
6.6.3 Business Strategies

List of Figures

  • Global Schizophrenia Market Value Forecast (2018-2023)
  • Global Schizophrenia Market Value by Mode of Administration (2018)
  • Global Long Acting Injections Schizophrenia Market Value Forecast (2018-2023)
  • Global Oral Schizophrenia Market Value Forecast (2018-2023)
  • Global Schizophrenia Market Value by Therapeutic Class (2018)
  • Global Second Generation Anti-Psychotic Market Value Forecast (2018-2023)
  • Global Third Generation Anti-Psychotic Market Value Forecast (2018-2023)
  • Global Schizophrenia Market Value by Drug Type (2018)
  • Global Invega Sustenna Drug Value Forecast (2018-2023)
  • Global Latuda Drug Value Forecast (2018-2023)
  • Global Aristada Drug Value Forecast (2018-2023)
  • Global Rexulti Drug Value Forecast (2018-2023)
  • Global Schizophrenia Market Value by Region (2018)
  • Americas Schizophrenia Market Value Forecast (2018-2023)
  • The U.S. Schizophrenia Market Value Forecast (2018-2023)
  • The U.S. Schizophrenia Value by Mode of Administration (2018)
  • The U.S. Long Acting Injections Schizophrenia Market Value Forecast (2018-2023)
  • The U.S. Oral Schizophrenia Market Value Forecast (2018-2023)
  • Europe Schizophrenia Market Value Forecast (2018-2023)
  • Europe Schizophrenia Value by Mode of Administration (2018)
  • Europe Oral Schizophrenia Market Value Forecast (2018-2023)
  • Europe Long Acting Injections Schizophrenia Market Value Forecast (2018-2023)
  • Germany Schizophrenia Market Value Forecast (2018-2023)
  • Asia-Pacific Schizophrenia Market Value Forecast (2018-2023)
  • Japan Schizophrenia Market Value Forecast (2018-2023)
  • The U.S. Schizophrenia Patient Population (2014-2018)
  • Global New Cancer Patients Volume (2014-2018)
  • Global Personal Healthcare Expenditure (2014-2018)
  • Global Gross Domestic Product (GDP) per Capita (2014-2018)
  • Global Pharmaceutical R&D Spending (2014-2018)
  • Global E-Commerce Pharmaceutical Products Sales (2018-2023)
  • Key Players – Market Cap Comparison (2019)
  • Key Players – Research & Development Expenditure Comparison (2017-2018)
  • Allergan Net Revenues and Net Loss (2014-2018)
  • Allergan Net Revenues by Segments (2018)
  • Allergan Net Revenues by Region (2018)
  • J&J Sales and Net Earnings (2014-2018)
  • J&J Sales by Segments (2018)
  • Otsuka Holdings Revenues and Profit (2014-2018)
  • Otsuka Holdings Revenues by Segment (2018)
  • Otsuka Holdings Revenues by Region (2018)
  • Sumitomo Chemicals Net Sales and Net Income (2015-2019)
  • Sumitomo Chemicals Net Sales by Segments (2019)
  • Alkermes Revenues and Net Loss (2014-2018)
  • Alkermes Revenues by Region (2018)
  • Acadia Pharmaceuticals Revenues and Net Loss (2014-2018)

List of Tables

  • Common Anti-Psychotics Approved for Schizophrenia Treatment
  • Upcoming Schizophrenia Drugs (2019-2023)
  • Key Players – Revenue Comparison (2018)
  • Key Players – Drug Features Comparison (2018)
  • Otsuka Holdings Segment Overview
  • Sumitomo Chemicals Segment Overview
  • Alkermes Product Pipeline Overview
  • Acadia Pharmaceuticals Product Pipeline Overview
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Acadia Pharmaceuticals Inc.
  • Alkermes Plc
  • Allergan Plc
  • Johnson & Johnson
  • Otsuka Holdings Co., Ltd.
  • Sumitomo Chemical Co., Ltd.
Note: Product cover images may vary from those shown
5 of 5

Loading
LOADING...

Adroll
adroll